Results for tag: "Xembify"

The Xembify market is a subset of the larger Immune Disorders Drugs market, which focuses on treatments for conditions such as allergies, asthma, and autoimmune diseases. Xembify is a type of monoclonal antibody therapy, which is a type of biologic drug that works by targeting specific proteins in the body. Xembify is used to treat a variety of immune-related conditions, including rheumatoid arthritis, Crohn's disease, and psoriasis. It is also used to treat certain types of cancer. Xembify is a relatively new type of therapy, and the market is still in its early stages. However, it is growing rapidly, with a number of companies developing and marketing Xembify-based treatments. Some of the major players in the Xembify market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Novartis. Show Less Read more